

EFFECTIVE DATE: 02 | 01 | 2005

POLICY LAST UPDATED: 01 | 21 | 2020

OVERVIEW

Lipoprotein-associated phospholipase A2 (Lp-PLA2), also known as platelet-activating factor acetylhydrolase is an enzyme that hydrolyzes phospholipids and is primarily associated with low-density lipoproteins (LDLs). Accumulating evidence has suggested that Lp-PLA2 is a biomarker of coronary artery disease (CAD) and may have a proinflammatory role in the progression of atherosclerosis.

For coverage of tests filed with PLA codes (0052U-VAP Cholesterol Test), please refer to the related policy “Proprietary Laboratory Analyses (PLA).”

MEDICAL CRITERIA

Not applicable

PRIOR AUTHORIZATION

Not applicable

POLICY STATEMENT

BlueCHiP for Medicare

Measurement of lipoprotein-associated phospholipase A2 (Lp-PLA2) is not covered as the evidence is insufficient to determine the effects of the technology on health outcomes.

Commercial Products

Measurement of lipoprotein-associated phospholipase A2 (Lp-PLA2) is considered not medically necessary as the evidence is insufficient to determine the effects of the technology on health outcomes.

COVERAGE

Benefits may vary between groups and contracts. Please refer to the appropriate Benefit Booklet, Evidence of Coverage or Subscriber Agreement for applicable not medically necessary/not covered benefits/coverage.

BACKGROUND

Low-density lipoproteins (LDL) have been identified as the major atherogenic lipoproteins and have long been identified by the National Cholesterol Education Project (NCEP) as the primary target of cholesterol-lowering therapy. LDL particles consist of a surface coat composed of phospholipids, free cholesterol, and apolipoproteins, surrounding an inner lipid core composed of cholesterol ester and triglycerides. Traditional lipid risk factors such as low-density lipoprotein-cholesterol (LDL-C), while predictive on a population basis, are weaker markers of risk on an individual basis. Only a minority of subjects with elevated LDL and cholesterol levels will develop clinical disease, and up to 50% of cases of coronary artery disease (CAD) occur in subjects with ‘normal’ levels of total and LDL cholesterol.

Although treatment for elevated coronary disease risk with statins targets cholesterol levels, selection for treatment involves estimation of future CAD risk using well-validated prediction models that use additional variables.

Lipoprotein-associated phospholipase A2 (Lp-PLA2), also known as platelet-activating factor acetylhydrolase, is an enzyme that hydrolyzes phospholipids and is primarily associated with LDLs. Accumulating evidence has suggested that Lp-PLA2 is a biomarker of CAD and may have a proinflammatory role in the progression of atherosclerosis. Recognition that atherosclerosis represents, in part, an inflammatory process has created considerable interest in measurement of proinflammatory factors as part of cardiovascular disease risk assessment.

Interest in Lp-PLA2 as a possibly causal risk factor for CAD has generated development and testing of Lp-PLA2 inhibitors as a new class of drugs to reduce risk of CAD. However, clinical trials of Lp-PLA2 inhibitors have not shown significant reductions in CAD end points. Furthermore, assessment of Lp-PLA2 levels has not been used in the selection or management of subjects in the clinical trials.

Regulatory Status

In December 2014, the PLAC® Test (diaDexus), a quantitative enzyme assay, was cleared for marketing by the U.S. Food and Drug Administration through the 510(k) process for Lp-PLA2 activity. It was considered substantially equivalent to a previous version of the PLAC® Test (diaDexus), which was cleared for marketing by the Food and Drug Administration in July 2003.

For individuals who have a risk of cardiovascular disease who receive Lp-PLA2 testing, the evidence includes studies of the association between Lp-PLA2 and various coronary artery disease outcomes. The relevant outcomes are overall survival, disease-specific survival, and test validity. The studies have demonstrated that Lp-PLA2 levels are an independent predictor of cardiovascular disease. Although Lp-PLA2 levels are associated with cardiovascular disease risk, changes in patient management that would occur as a result of obtaining Lp-PLA2 levels in practice are not well-defined. To demonstrate clinical utility, clinicians must have the tools to incorporate Lp-PLA2 test results into existing risk prediction models that improve classification into risk categories alter treatment decisions and lead to improved health outcomes. Direct evidence for such improved health outcomes with Lp-PLA2 testing in clinical practice is lacking. The evidence is insufficient to determine the effects of the technology on health outcomes. Therefore, this service is not covered for BlueCHiP for Medicare and not medically necessary for Commercial products.

CODING

The following code is not covered for BlueCHiP for Medicare and not medically necessary for Commercial products:

83698 Lipoprotein-associated phospholipase A₂, (Lp-PLA₂)

RELATED POLICIES

Proprietary Laboratory Analyses (PLA)

PUBLISHED

Provider Update, March 2020

Provider Update, September 2019

Provider Update, Nov. /Dec. 2018

Provider Update, November 2017

Provider Update, January 2017

Provider Update, October 2015

Provider Update, January 2014

REFERENCES

1. Stability Investigators, White HD, Held C, et al. Darapladib for preventing ischemic events in stable coronary heart disease. *N Engl J Med.* May 1 2014;370(18):1702-1711. PMID 24678955
2. O'Donoghue ML, Braunwald E, White HD, et al. Effect of darapladib on major coronary events after an acute coronary syndrome: the SOLID-TIMI 52 randomized clinical trial. *JAMA.* Sep 10 2014;312(10):1006-1015. PMID 25173516

3. Nicholls SJ, Kastelein JJ, Schwartz GG, et al. Varespladib and cardiovascular events in patients with an acute coronary syndrome: the VISTA-16 randomized clinical trial. *JAMA*. Jan 15 2014;311(3):252-262. PMID 24247616
4. National Institutes of Health, National Heart Lung and Blood Institute. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) (NIH Publication No. 01-3670). 2001; <http://www.nhlbi.nih.gov/guidelines/cholesterol/atp3xsum.pdf> Accessed November 16, 2017.
5. Wallentin L, Held C, Armstrong PW, et al. Lipoprotein-associated phospholipase A2 activity is a marker of risk but not a useful target for treatment in patients with stable coronary heart disease. *J Am Heart Assoc*. Jun 21 2016;5(6). PMID 27329448
6. Food and Drug Administration (FDA). 510(K) Summary -- diaDexus PLAC Test. 2013; http://www.accessdata.fda.gov/cdrh_docs/pdf3/K030477.pdf. Accessed November 16, 2017.
7. Emerging Risk Factors Collaboration, Di Angelantonio E, Gao P, et al. Lipid-related markers and cardiovascular disease prediction. *JAMA*. Jun 20 2012;307(23):2499-2506. PMID 22797450
8. Garza CA, Montori VM, McConnell JP, et al. Association between lipoprotein-associated phospholipase A2 and cardiovascular disease: a systematic review. *Mayo Clin Proc*. Feb 2007;82(2):159-165. PMID 17290721
9. Thompson A, Gao P, Orfei L, et al. Lipoprotein-associated phospholipase A(2) and risk of coronary disease, stroke, and mortality: collaborative analysis of 32 prospective studies. *Lancet*. May 1 2010;375(9725):1536-1544. PMID 20435228
10. Packard CJ, O'Reilly DS, Caslake MJ, et al. Lipoprotein-associated phospholipase A2 as an independent predictor of coronary heart disease. West of Scotland Coronary Prevention Study Group. *N Engl J Med*. Oct 19 2000;343(16):1148-1155. PMID 11036120
11. Ballantyne CM, Hoogeveen RC, Bang H, et al. Lipoprotein-associated phospholipase A2, high-sensitivity C-reactive protein, and risk for incident coronary heart disease in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) study. *Circulation*. Feb 24 2004;109(7):837-842. PMID 14757686
12. Koenig W, Khuseyinova N, Lowel H, et al. Lipoprotein-associated phospholipase A2 adds to risk prediction of incident coronary events by C-reactive protein in apparently healthy middle-aged men from the general population: results from the 14-year follow-up of a large cohort from southern Germany. *Circulation*. Oct 5 2004;110(14):1903-1908. PMID 15451783
13. Ballantyne CM, Hoogeveen RC, Bang H, et al. Lipoprotein-associated phospholipase A2, high-sensitivity C-reactive protein, and risk for incident ischemic stroke in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) study. *Arch Intern Med*. Nov 28 2005;165(21):2479-2484. PMID 16314544
14. Sabatine MS, Morrow DA, O'Donoghue M, et al. Prognostic utility of lipoprotein-associated phospholipase A2 for cardiovascular outcomes in patients with stable coronary artery disease. *Arterioscler Thromb Vasc Biol*. Nov 2007;27(11):2463-2469. PMID 17766330
15. Winkler K, Hoffmann MM, Winkelmann BR, et al. Lipoprotein-associated phospholipase A2 predicts 5-year cardiac mortality independently of established risk factors and adds prognostic information in patients with low and medium high-sensitivity C-reactive protein (the Ludwigshafen risk and cardiovascular health study). *Clin Chem*. Aug 2007;53(8):1440-1447. PMID 17573419
16. Persson M, Hedblad B, Nelson JJ, et al. Elevated Lp-PLA2 levels add prognostic information to the metabolic syndrome on incidence of cardiovascular events among middle-aged nondiabetic subjects. *Arterioscler Thromb Vasc Biol*. Jun 2007;27(6):1411-1416. PMID 17431184
17. Daniels LB, Laughlin GA, Sarno MJ, et al. Lipoprotein-associated phospholipase A2 is an independent predictor of incident coronary heart disease in an apparently healthy older population: the Rancho Bernardo Study. *J Am Coll Cardiol*. Mar 4 2008;51(9):913-919. PMID 18308160
18. Hatoum IJ, Cook NR, Nelson JJ, et al. Lipoprotein-associated phospholipase A2 activity improves risk discrimination of incident coronary heart disease among women. *Am Heart J*. Mar 2011;161(3):516-522. PMID 21392606
19. Liu YS, Hu XB, Li HZ, et al. Association of lipoprotein-associated phospholipase A(2) with characteristics of vulnerable coronary atherosclerotic plaques. *Yonsei Med J*. Nov 2011;52(6):914-922. PMID 22028154

20. Sarlon-Bartoli G, Boudes A, Buffat C, et al. Circulating lipoprotein-associated phospholipase A2 in high-grade carotid stenosis: a new biomarker for predicting unstable plaque. *Eur J Vasc Endovasc Surg.* Feb 2012;43(2):154-159. PMID 22075154
21. Liu CF, Qin L, Ren JY, et al. Elevated plasma lipoprotein-associated phospholipase A(2) activity is associated with plaque rupture in patients with coronary artery disease. *Chin Med J (Engl).* Aug 2011;124(16):2469-2473. PMID 21933589
22. Gu X, Hou J, Yang S, et al. Is lipoprotein-associated phospholipase A2 activity correlated with fibrous-cap thickness and plaque volume in patients with acute coronary syndrome? *Coron Artery Dis.* Jan 2014;25(1):10-15. PMID 24089018
23. Muller O, Ntalianis A, Wijns W, et al. Association of biomarkers of lipid modification with functional and morphological indices of coronary stenosis severity in stable coronary artery disease. *J Cardiovasc Transl Res.* Aug 2013;6(4):536-544. PMID 23670230
24. Tehrani DM, Gardin JM, Yanez D, et al. Impact of inflammatory biomarkers on relation of high density lipoprotein-cholesterol with incident coronary heart disease: cardiovascular Health Study. *Atherosclerosis.* Dec 2013;231(2):246-251. PMID 24267235
25. Jellinger PS, Handelsman Y, Rosenblit PD, et al. American Association of Clinical Endocrinologists and American College of Endocrinology Guidelines for Management of Dyslipidemia and Prevention of Cardiovascular Disease. *Endocr Pract.* Apr 2017;23(Suppl 2):1-87. PMID 28437620

CLICK THE ENVELOPE ICON BELOW TO SUBMIT COMMENTS

This medical policy is made available to you for informational purposes only. It is not a guarantee of payment or a substitute for your medical judgment in the treatment of your patients. Benefits and eligibility are determined by the member's subscriber agreement or member certificate and/or the employer agreement, and those documents will supersede the provisions of this medical policy. For information on member-specific benefits, call the provider call center. If you provide services to a member which are determined to not be medically necessary (or in some cases medically necessary services which are non-covered benefits), you may not charge the member for the services unless you have informed the member and they have agreed in writing in advance to continue with the treatment at their own expense. Please refer to your participation agreement(s) for the applicable provisions. This policy is current at the time of publication; however, medical practices, technology, and knowledge are constantly changing. BCBSRI reserves the right to review and revise this policy for any reason and at any time, with or without notice. Blue Cross & Blue Shield of Rhode Island is an independent licensee of the Blue Cross and Blue Shield Association.

